Oncology KOL Intelligence, decoded.

Oct 26, 2026, 6:06:19 AM Brian Shields

ESMO 2026 Day 3: Top Trials and KOL Reactions

ESMO 2026 Day 3: KRASCENDO-1 and the crossover question, SAFFRON, HARMONi-GI1, CLARITY-Gastric01, PERSEE, LITESPARK-012, NADINA and more, with physician reactio…

lung cancerbreast cancerkol reactions

Oct 25, 2026, 7:42:21 AM Brian Shields

ESMO 2026: Top GU Cancer Trials and KOL Voices

ESMO 2026 Madrid GU cancers, October 23–26: VOLGA, KEYNOTE-866, DASL-HiCaP, LITESPARK-012 and TALAPRO-3, FDA approved October 26, with verbatim physician reacti…

kol reactionsesmo 2026bladder cancer

Oct 25, 2026, 4:04:36 AM Brian Shields

ESMO 2026 Days 1–2: Top Trials and KOL Reactions

ESMO 2026 Days 1-2: a standing ovation for DeLLphi-305 and the crossover question physicians raised, plus INTerpath-001, VOLGA, NATALEE, PANKU-Breast01 and more…

lung cancerbreast cancerkol reactions

Oct 24, 2026, 12:19:39 PM Brian Shields

The ESMO 2026 Debates from the KOL Social Media Threads

ESMO 2026 physician debates on X, verbatim: INTerpath-001 vs neoadjuvant IO, NATALEE's nominal OS p-value, me-too HER2 ADCs, pCR vs EFS in bladder cancer, KEYNO…

breast cancerkol reactionsesmo 2026

Oct 24, 2026, 2:32:23 AM Brian Shields

ENERGIZE and KEYNOTE-866: Two Negative Phase 3 MIBC Trials at ESMO 2026, and the NIAGARA Question

ESMO 2026: perioperative nivolumab (ENERGIZE, EFS HR 0.94) and pembrolizumab (KEYNOTE-866, EFS HR 0.88, OS HR 1.00) with gem/cis did not improve EFS in cisplati…

mibckol reactionsesmo 2026